The RoslinCT-Lykan combination creates an innovative advanced therapies contract development and manufacturing organization (CDMO) with process and analytical development laboratories and cGMP manufacturing facilities located in Hopkinton, Massachusetts and Edinburgh, Scotland. The combined group will offer process development expertise and cGMP manufacturing for a broad range of autologous and allogeneic cell therapies, with unparalleled expertise in gene editing and industry-leading induced Pluripotent Stem Cell (iPSC) capabilities.
For full information please click here.